Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Major Depressive Disorder (MDD) AND Major Depressive Disorder AND Placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    160 result(s) found for: Major Depressive Disorder (MDD) AND Major Depressive Disorder AND Placebo. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2010-022257-41 Sponsor Protocol Number: Lu AA21004/CCT-002 Start Date*: 2010-12-07
    Sponsor Name:Takeda Global Research and Development Centre (Europe) Ltd.
    Full Title: A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder
    Medical condition: major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025454 Major depressive disorder, recurrent episode LLT
    12.1 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) FI (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-001950-25 Sponsor Protocol Number: VLZ-MD-02 Start Date*: 2013-03-06
    Sponsor Name:Forest Research Institute, Inc., a wholly owned subsidiary of Forest Laboratories, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    18.0 100000004873 10025453 Major depressive disorder NOS LLT
    18.0 100000004873 10053708 Major depressive disorder with melancholic features LLT
    18.0 100000004873 10067465 Major depressive disorder aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-001380-76 Sponsor Protocol Number: 14570A Start Date*: 2013-03-28
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole a...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025461 Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behavior LLT
    18.0 100000004873 10025463 Major depressive disorder, single episode LLT
    18.0 100000004873 10025469 Major depressive disorder, single episode, severe degree, without mention of psychotic behavior LLT
    18.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    18.0 100000004873 10025467 Major depressive disorder, single episode, moderate degree LLT
    18.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    18.0 100000004873 10025470 Major depressive disorder, single episode, unspecified degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) SE (Completed) FI (Completed) LT (Completed) GB (Completed) BG (Completed) IT (Prematurely Ended) LV (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002160-24 Sponsor Protocol Number: BP25712 Start Date*: 2012-04-12
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients with Major D...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2009-011795-29 Sponsor Protocol Number: CL3-20098-070 Start Date*: 2009-09-04
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomised, double-blind, flexible-dose, parallel gr...
    Medical condition: Major Depression
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002740-16 Sponsor Protocol Number: ME1-1 Start Date*: 2007-08-23
    Sponsor Name:M's Science Corporation
    Full Title: A Phase II, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment with SA4503, 1 mg or 3 mg Once Daily for 8 Weeks, in S...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005179-18 Sponsor Protocol Number: RGH-MD-75 Start Date*: 2012-03-12
    Sponsor Name:Forest Research Institute, Inc
    Full Title: A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder.
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025463 Major depressive disorder, single episode LLT
    14.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005578-39 Sponsor Protocol Number: PKI108574 Start Date*: 2007-01-18
    Sponsor Name:GlaxoSmithKline
    Full Title: A randomised, double-blind, placebo-controlled study to explore the antidepressant properties of the P38a kinase inhibitor GW856553X 15mg compared to placebo in subjects with Major Depressive Disor...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017523-26 Sponsor Protocol Number: 13267A Start Date*: 2010-05-11
    Sponsor Name:H. Lundbeck A/S
    Full Title: A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025453 Major depressive disorder NOS LLT
    12.1 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) DE (Completed) EE (Completed) SK (Completed) LV (Completed) LT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000439-22 Sponsor Protocol Number: 67953964MDD3001_VENTURA-1 Start Date*: 2023-03-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) ES (Ongoing) HU (Completed) BE (Completed) BG (Completed) PT (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014045-92 Sponsor Protocol Number: CL2-90098-009 Start Date*: 2010-01-12
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomis...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) CZ (Completed) SE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003159-36 Sponsor Protocol Number: EFC10290 Start Date*: 2007-10-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patient...
    Medical condition: Treatment of Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000338-16 Sponsor Protocol Number: 42847922MDD3002 Start Date*: 2020-10-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Eld...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) FI (Prematurely Ended) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-001622-26 Sponsor Protocol Number: QQ05.16.02 Start Date*: 2018-08-14
    Sponsor Name:FIDIA FARMACEUTICI S.P.A.
    Full Title: A randomized, double-blind, placebo-controlled, multicenter clinical trial to assess safety and effectiveness of Liposom in enhance and speed up response to antidepressant therapy with citalopram i...
    Medical condition: Major Depressive Disorder (MDD) in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003863-31 Sponsor Protocol Number: EFC10438 Start Date*: 2008-04-25
    Sponsor Name:Sanofi-Aventis recherche & développement
    Full Title: An eight-week, double-blind study to evaluate the efficacy, safety, and tolerability of two fixed doses of saredutant (100 mg and 30 mg) once daily in combination with paroxetine 20 mg once daily c...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019925-33 Sponsor Protocol Number: D4130C00003 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in ...
    Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    13.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) LT (Completed) EE (Completed) LV (Completed) CZ (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-013110-27 Sponsor Protocol Number: D2285C00001 Start Date*: 2009-08-17
    Sponsor Name:AstraZeneca AB
    Full Title: A phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female patients fulfilling the criteria for Major Depressive ...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    12.0 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000230-34 Sponsor Protocol Number: 15906A Start Date*: 2014-09-23
    Sponsor Name:H. Lundbeck A/S
    Full Title: An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working...
    Medical condition: Major depressive disorder and cognitive impairment
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) FI (Completed) LT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000461-41 Sponsor Protocol Number: 67953964MDD3002 Start Date*: 2023-02-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) FR (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000167-95 Sponsor Protocol Number: Protocol F1J-MC-HMDI Start Date*: 2005-03-03
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 07:59:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA